An Open-Label, Randomized Study of Low-Dose Cytarabine in Combination With Arsenic Trioxide Compared With Low-Dose Cytarabine Alone for the Treatment of Elderly Patients With Acute Myeloid Leukaemia.

Trial Profile

An Open-Label, Randomized Study of Low-Dose Cytarabine in Combination With Arsenic Trioxide Compared With Low-Dose Cytarabine Alone for the Treatment of Elderly Patients With Acute Myeloid Leukaemia.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 31 Jul 2012

At a glance

  • Drugs Arsenic trioxide (Primary) ; Cytarabine
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Sponsors Cephalon
  • Most Recent Events

    • 31 Jul 2012 Company (Teva Pharmaceutical Industries) added as an association as reported by ClinicalTrials.gov record.
    • 28 Mar 2011 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
    • 27 Apr 2010 Actual patient number (67) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top